Filtered By:
Source: American Heart Journal
Therapy: Statin Therapy
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 32 results found since Jan 2013.
Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER): Implementing the Patient-Driven Research Paradigm to Aid Decision Making in Stroke Care
Conclusions PROSPER is a patient-centered outcomes research study guided by patients, caregivers, and the broader healthcare community. By addressing knowledge gaps in treatment uncertainties through comparative effectiveness research, PROSPER has the potential to improve decision-making in stroke care and patient outcomes reflecting individual patient preferences, needs, and values.
Source: American Heart Journal - April 22, 2015 Category: Cardiology Source Type: research
Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research: Implementing the patient-driven research paradigm to aid decision making in stroke care
Conclusions PROSPER is a patient-centered outcome research study guided by patients, caregivers, and the broader health care community. By addressing knowledge gaps in treatment uncertainties through comparative effectiveness research, PROSPER has the potential to improve decision making in stroke care and patient outcomes reflecting individual patient preferences, needs, and values.
Source: American Heart Journal - May 11, 2015 Category: Cardiology Source Type: research
Anatomic Runoff Score Predicts Cardiovascular Outcomes in Patients with Lower Extremity Peripheral Artery Disease Undergoing Revascularization
Conclusions After adjustment for clinical factors, the LE-PAD anatomic runoff score was an independent predictor of future cardiovascular morbidity and mortality in a broadly-representative patient population undergoing revascularization for symptomatic PAD. A clinically useful anatomic scoring system, if validated, may assist clinicians in risk-stratification during the course of clinical decision-making.
Source: American Heart Journal - May 2, 2015 Category: Cardiology Source Type: research
Rationale and Design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk (FOURIER) Trial
Conclusions FOURIER will determine whether the addition of evolocumab to statin therapy reduces cardiovascular morbidity and mortality in patients with vascular disease.
Source: American Heart Journal - December 17, 2015 Category: Cardiology Source Type: research
Atorvastatin for High Risk Statin-Na ïve Patients Undergoing Noncardiac Surgery: The LOAD Randomized Trial
Conclusion In contrast to the prior observational and trial data, the LOAD trial has neutral results and did not demonstrate a reduction in major cardiovascular complications after a short-term perioperative course of statin in statin-naïve patients undergoing non-cardiac surgery. We demonstrated, however, that a large multicenter blinded perioperative statin trial for high risk statin-naïve patients is feasible, and should be done to definitely establish the efficacy and safety of statin in this patient population. Clinical trial registration: Clinicaltrials.gov Identifier: NCT01543555
Source: American Heart Journal - November 9, 2016 Category: Cardiology Source Type: research
Atorvastatin for high-risk statin-na ïve patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial
Conclusion In contrast to the prior observational and trial data, the LOAD trial has neutral results and did not demonstrate a reduction in major cardiovascular complications after a short-term perioperative course of statin in statin-naïve patients undergoing noncardiac surgery. We demonstrated, however, that a large multicenter blinded perioperative statin trial for high-risk statin-naïve patients is feasible and should be done to definitely establish the efficacy and safety of statin in this patient population.
Source: American Heart Journal - November 25, 2016 Category: Cardiology Source Type: research
Effect of High-Dose Oral Multi-Vitamins and Minerals in Participants Not Treated with Statins in the Randomized Trial to Assess Chelation Therapy
Conclusion and Relevance High-dose oral multi-vitamin and multi-mineral supplementation appear to decrease combined cardiac events in a stable, post-MI population not taking statin therapy at baseline. These unexpected findings are being retested in the ongoing TACT2.
Source: American Heart Journal - September 9, 2017 Category: Cardiology Source Type: research
Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT)
Conclusion and relevance High-dose oral multivitamin and multimineral supplementation seem to decrease combined cardiac events in a stable, post-MI population not taking statin therapy at baseline. These unexpected findings are being retested in the ongoing TACT2.
Source: American Heart Journal - November 9, 2017 Category: Cardiology Source Type: research
EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy
This report describes the intent-to-treat comparison of the 4 factorial groups overall and in patients with diabetes.Methods: This was a double-blind, placebo-controlled, 2 × 2 factorial multicenter randomized trial of 1,708 post–myocardial infarction (MI) patients ≥50 years of age and with creatinine ≤2.0 mg/dL randomized to receive 40 EDTA chelation or placebo infusions plus 6 caplets daily of a 28-component multivitamin-multimineral mixture or placebo. The primary end point was a composite of total mortality, MI, stroke, coronary revascularization, or hospitalization for angina.Results: Median age was 65 years, 1...
Source: American Heart Journal - April 4, 2014 Category: Cardiology Authors: Gervasio A. Lamas, Robin Boineau, Christine Goertz, Daniel B. Mark, Yves Rosenberg, Mario Stylianou, Theodore Rozema, Richard L. Nahin, L. Terry Chappell, Lauren Lindblad, Eldrin F. Lewis, Jeanne Drisko, Kerry L. Lee Tags: Coronary Artery Disease Source Type: research
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population
Background: The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) is evaluating the potential benefit for reduction in major cardiovascular (CV) events from the addition of ezetimibe versus placebo to 40 mg/d of simvastatin therapy in patients who present with acute coronary syndromes and have low-density lipoprotein cholesterol (LDL-C) ≤125 mg/dL.Methods: The primary composite end point is CV death, nonfatal myocardial infarction (MI), nonfatal stroke, rehospitalization for unstable angina (UA), and coronary revascularization (≥30 days postrandomization). The simvastatin monotherapy arm’s LDL-C target is
Source: American Heart Journal - May 19, 2014 Category: Cardiology Authors: Michael A. Blazing, Robert P. Giugliano, Christopher P. Cannon, Thomas A. Musliner, Andrew M. Tershakovec, Jennifer A. White, Craig Reist, Amy McCagg, Eugene Braunwald, Robert M. Califf Tags: Acute Ischemic Heart Disease Source Type: research
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
Publication date: Available online 7 August 2014 Source:American Heart Journal Author(s): Gregory G. Schwartz , Laurence Bessac , Lisa G. Berdan , Deepak L. Bhatt , Vera Bittner , Rafael Diaz , Shaun G. Goodman , Corinne Hanotin , Robert A. Harrington , J. Wouter Jukema , Kenneth W. Mahaffey , Angèle Moryusef , Robert Pordy , Matthew T. Roe , Tyrus Rorick , William J. Sasiela , Cheerag Shirodaria , Michael Szarek , Jean-François Tamby , Pierluigi Tricoci , Harvey White , Andreas Zeiher , Philippe Gabriel Steg Following acute coronary syndrome (ACS), the risk for future cardiovascular events is high and is related to le...
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population
Conclusions This trial is evaluating LDL-C lowering beyond previously targeted LDL-C levels. The results depend on achieving the desired separation of LDL-C with ezetimibe and on the assumption that ezetimibe’s lowering of LDL-C will have similar event reduction efficacy as the LDL-C lowering from a statin. The results could affect future therapies and guidelines.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research
EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy
Conclusions In stable post-MI patients on evidence-based medical therapy, the combination of oral high-dose vitamins and chelation therapy compared with double placebo reduced clinically important cardiovascular events to an extent that was both statistically significant and of potential clinical relevance.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research
Applicability and potential clinical effects of 2013 cholesterol guidelines on major cardiovascular events
Conclusions In the Korean population, the 2013 ACC/AHA cholesterol guidelines would substantially increase the number of adults who are potentially eligible for statin therapy and would recommend statin therapy for more adults at higher cardiovascular risk. However, the clinician-patient discussion of the potential benefits, possible harms, and other factors before the initiation of statin therapy must be considered.
Source: American Heart Journal - September 15, 2015 Category: Cardiology Source Type: research
Protocol for analyses of adverse event data from randomized controlled trials of statin therapy
Publication date: Available online 28 January 2016 Source:American Heart Journal Author(s): C. Reith, L. Blackwell, J. Emberson, B. Mihaylova, J. Armitage, J. Fulcher, A. Keech, J. Simes, C. Baigent, R. Collins The Cholesterol Treatment Trialists’ (CTT) Collaboration was originally established to conduct individual patient data meta-analyses of major vascular events, cause-specific mortality and site-specific cancers in large, long-term, randomized trials of statin therapy (and other cholesterol-modifying treatments). The results of the trials of statin therapy, and their associated meta-analyses, have shown ...
Source: American Heart Journal - January 30, 2016 Category: Cardiology Source Type: research
